SYNEXUS Trademark

Trademark Overview

On Friday, July 22, 2022, a trademark application was filed for SYNEXUS with the United States Patent and Trademark Office. The USPTO has given the SYNEXUS trademark a serial number of 97516475. The federal status of this trademark filing is EX PARTE APPEAL PENDING as of Thursday, December 5, 2024. This trademark is owned by Synexus Clinical Research US, Inc.. The SYNEXUS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Clinical, chemical and medical research services in the field of pharmaceutical drugs, medical devices and clinical trials; scientific, clinical and industrial research and analysis services in the field of pharmaceutical drugs, medical devices and clinical trials; Medical and scientific research, namely, conducting clinical trials for others

General Information

Serial Number97516475
Word MarkSYNEXUS
Filing DateFriday, July 22, 2022
Status760 - EX PARTE APPEAL PENDING
Status DateThursday, December 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesClinical, chemical and medical research services in the field of pharmaceutical drugs, medical devices and clinical trials; scientific, clinical and industrial research and analysis services in the field of pharmaceutical drugs, medical devices and clinical trials; Medical and scientific research, namely, conducting clinical trials for others

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, August 15, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSynexus Clinical Research US, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWilmington, NC 28401

Trademark Events

Event DateEvent Description
Wednesday, July 27, 2022NEW APPLICATION ENTERED
Monday, August 15, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 9, 2023ASSIGNED TO EXAMINER
Thursday, May 25, 2023NON-FINAL ACTION WRITTEN
Thursday, May 25, 2023NON-FINAL ACTION E-MAILED
Thursday, May 25, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, August 24, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 24, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 25, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 29, 2023NON-FINAL ACTION WRITTEN
Friday, September 29, 2023NON-FINAL ACTION E-MAILED
Friday, September 29, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, December 27, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, December 27, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, March 29, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 29, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 29, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 24, 2024FINAL REFUSAL E-MAILED
Wednesday, April 24, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, April 24, 2024FINAL REFUSAL WRITTEN
Wednesday, July 24, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, July 24, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Thursday, October 24, 2024EXPARTE APPEAL RECEIVED AT TTAB
Thursday, October 24, 2024JURISDICTION RESTORED TO EXAMINING ATTORNEY
Thursday, October 24, 2024EX PARTE APPEAL-INSTITUTED
Thursday, October 24, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, December 5, 2024ACTION CONTINUING FINAL - COMPLETED
Thursday, December 5, 2024NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Thursday, December 5, 2024ACTION DENYING REQ FOR RECON E-MAILED

Related Keywords

synexus clinical medical trials research devices scientific drugs pharmaceutical services field